Effect of Urosodeoxycholic Acid in the Treatment of Hepatitis A

Phase 3

• Conditions: Hepatitis A without hepatic coma; Hepatitis A.

• Registration Number: IRCT20171113037429N1
• Lead Sponsor: Zabol University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Having Coagulopathy
Encephalopathy
Positive Anti HAV

Exclusion Criteria

HAV Positive up to 6 months
Abdominal pain
Changing the Color of the Urine and Stool
Icter
Using any other drugs

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Measurement of Alanine aminotransferase liver enzyme. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.;Measurement of Aspartate Aminotransferase liver enzyme. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.

Secondary Outcome Measures

Name	Time	Method
Measurement of serum alkaline phosphatase. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.;Measurement of Serum albumin. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.;Measurement of Serum bilirubin. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.